Filter results
05/09/2019
The new plant will manufacture the active substances for low-molecular-weight heparins
30/07/2019
Operating income, growth figures, profitability and how our products have behaved
30/07/2019
Download our press release published on 30 July to find out the financial results for the first half 2019
05/07/2019
The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the monthly injectable antipsychotic for the treatment of patients with acute exacerbation of schizophrenia.
08/05/2019
Operating income, growth figures, profitability and how our products have behaved
08/05/2019
Download our press release published on 8 May to find out the financial results for the first quarter 2019
19/03/2019
Advanced Final Results from the Pivotal Study of its Once-monthly Injectable Antipsychotic show that Primary and Key Secondary Efficacy Endpoints Were Achieved with Both Doses Tested for the Treatment of Patients with Acute Exacerbation of Schizophrenia
26/02/2019
Operating income, growth figures, profitability and how our products have behaved.